InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,633.91
(
1.02%
)
US TECH 100
20,107.60
(
0.99%
)
Dow Jones
39,721.36
(
1.09%
)
Brent Oil
85.40
(
0.41%
)
Bitcoin
57,918.06
(
0.28%
)
Post# of 690
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

NASDAQ2020

Send PM Follow Ignore
Followers 188
Posts 29010
Boards Moderated 1
Alias Born 08/29/2012

NASDAQ2020

Re: None

Wednesday, 03/10/2021 8:55:03 PM

Wednesday, March 10, 2021 8:55:03 PM

Post# of 690
PHILADELPHIA, March 10, 2021 /PRNewswire/ -- Lannett Company, Inc. (NYSE: LCI) today announced that it recently received feedback from the U.S. Food and Drug Administration (FDA) regarding biosimilar insulin glargine, a product the company is co-developing with its strategic alliance partners within the HEC Group of companies (HEC). Lannett sought and received comments from the FDA related to the pivotal trial protocol and statistical analysis plan (SAP) for the development program.

LCI (NYSE) $7.14 +0.59 (+9.09%)
Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up